Looking beyond Roche’s Tigit bombshell
The failure of Skyscraper-01 calls into question Roche’s vast investment in Tigit blockade, but is there broader significance?
Roche’s Tigit fail poses a big question for Merck
Roche just showed that adding Tigit to PD-(L)1 blockade is a non-starter in SCLC, and now Merck & Co risks doing the same.
Arcus’s near dream scenario
Gilead opts in at long last, and that’s more than many might have been expecting.
Astra presses on with bispecifics
Followers of novel immuno-oncology mechanisms will note Astrazeneca as a new player in Tigit and Tim3.
Crucial clinical events for the smaller players
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
Reading Arcus’s Tigit tea leaves
As data non-disclosure prompts sellside guesswork one indisputable fact stands out: Gilead has not opted in to Arcus’s domvanalimab.
Arcus nears crunch time for Gilead opt-in
The anti-Tigit MAb domvanalimab will generate key clinical results any day; will they be good enough for Gilead to opt in?
